Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Vedolizumab
Monoclonal Antibody · Treatment for Inflammatory Bowel Disease
Monoclonal AntibodyTreatment for Inflammatory Bowel Disease
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Vedolizumab is a humanized monoclonal antibody that targets the "4β7 integrin in the gastrointestinal tract. It inhibits white blood cell (WBC) migration or action by preventing binding to its receptor. It does not appear to induce systemic immunosuppression of other 4β7 integrin-binding antibodies such as natalizumab because it does not bind to the majority of 4β7 integrin on lymphocytes.
Indications
Moderate to severely active Crohn’s disease (when therapy with adalimumab or infliximab is unsuccessful, contraindicated or not tolerated)Treatment of adults with Crohn’s diseaseTreatment of adults with Ulcerative colitisCrohn's diseaseUlcerative colitismoderately to severely active crohn’s diseasemoderately to severely active ulcerative colitismoderate-to-severe Crohn’s disease
Dosing
- Adult
- Generally given at a dose of 300 mg at 0, 2, and 6 weeks, with maintenance doses of 300 mg given every 8 weeks thereafter.
Side effects
Common
increased risk of infectionshepatotoxicityheadachehypersensitivity reactionsarthralgianasopharyngitisfatigue
Serious
- increased risk of pml (only one case reported, but monitoring recommended)
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: others
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Clinical effect not specified
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Gastric premalignant conditions
ACG · Gastroenterology · 2025
Coeliac disease
OTHER · Gastroenterology · 2016
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Other Monoclonal Antibody drugs
Ask House about Vedolizumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF, Nelson·Verified: 2026-05-10 · House clinical team